PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22517690-8	2012	HP showed statistically significant difference between DC (55; 83.3%) and LC (11; 16.7%) patients with HER-2 amplification (p<0.01).	Deoxycytidine	55-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108	
32861882-2	2020	We aimed to analyse the survival outcomes of patients with node negative and human epidermal growth factor receptor (HER2)-negative breast cancer treated with four cycles of DC.	Deoxycytidine	174-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121